Inpare ApS: Financial statements 2023
CVR: 37138789
Source: annual report 2023, Danish Business Authority
01/01/2023 – 31/12/2023
Inpare ApS (CVR 37138789) has filed annual accounts for 2023. In 2023, the company reported a gross profit of DKK -218,796 and a net result of DKK -272,847 compared with DKK -142,714 the year before. Equity in the 2023 report amounted to DKK -735,535.
- Gross Profit
- DKK -218,796
- Profit/Loss
- DKK -272,847
- Equity
- DKK -735,535
- Total Assets
- DKK 81,253
- Employees
- 0
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2023 | - | -219K | -273K | -736K | 0 |
| 2022 | - | -118K | -143K | -463K | - |
| 2021 | - | -98K | -77K | -320K | - |
| 2020 | - | -197K | -133K | -243K | 2 |
| 2019 | - | -100K | -78K | -110K | 2 |
Official annual report
Fetch this data via API
Every Danish company, financial statement and ownership record, straight into your own systems or your AI assistant via MCP.
See the API documentationEvents in 2023
As of September 7, 2023, Claus Juan Møller-San Pedro is registered as adm. dir. of Inpare ApS.
As of September 7, 2023, Søren Anker Nielsen has stepped down as adm. dir. of Inpare ApS.
As of May 17, 2023, Søren Anker Nielsen is registered as adm. dir. of Inpare ApS.
As of May 17, 2023, Per Holm has stepped down as chairman of Inpare ApS.
As of May 17, 2023, Per Holm has stepped down as director of Inpare ApS.
On May 17, 2023, the company changed its name from Lionheart Pharmaceuticals ApS to Inpare ApS.
Inpare ApS has published its annual report for 2022. Gross profit came to DKK -118,415, and the net result was DKK -142,714.
As of January 22, 2023, Ole Pedersen has left the board of directors of Inpare ApS.
As of January 22, 2023, Ole Pedersen has stepped down as director of Inpare ApS.
About Inpare ApS
Inpare ApS was a Danish company of the type Anpartsselskab based in Hørsholm, founded in 2015. The company has been dissolved on 27 November 2024. The company was registered under the industry Fremstilling af farmaceutiske præparater. The company was previously named Lionheart Pharmaceuticals ApS. According to the 2023 annual report, the company had an average of 0 employees. In 2023, the company reported a gross profit of DKK -218,796 and a net result of DKK -272,847 compared with DKK -142,714 the year before. Equity in the 2023 report amounted to DKK -735,535.